Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS RATING: 5.23, Impact Factor: RJIF 5.98 | Free Publication Certificate
updates
NAAS Rating: 5.23 new
Vol. 6, Issue 3 (2017)

Ranolazine: Antianginal medicine or more?

Author(s):
Sergiy Fedorov
Abstract:
Ranolazine, a piperazine derivative sold, is a well‐tolerated medication that selectively inhibits the late sodium current. It has beneficial metabolic properties and does not affect heart rate or blood pressure. Ranolazine is currently approved in the United States and Europe as a second‐line agent in the management of stable angina pectoris. In this review we showed that ranolazine is perspective medication for arrhythmia treatment.
Pages: 232-234  |  659 Views  11 Downloads
How to cite this article:
Sergiy Fedorov. Ranolazine: Antianginal medicine or more?. Pharma Innovation 2017;6(3):232-234.
The Pharma Innovation Journal